Peptide Library

Human study PLS-00176

Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment.primary · Human pathology · 2006-09-01 · PMID 16949646 · DOI

Design and participants

Design
Other design
Population
Human breast cancer tumor specimens examined for cellular localization of endogenous thymosin beta4
Conditions
Breast cancer
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (publication type); funder not named in record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Several cell types in the breast tumor microenvironment produce thymosin beta4, and expression varies between tumors. The authors say this heterogeneity should be considered when assessing the role of thymosin beta4 in tumor biology.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: Tissue specimens from breast cancer patients examined for endogenous expression; no one received thymosin beta4 as an intervention.
    • abstract only: Only the abstract is available; sample size, methods and quantitative results are not reported in the record.
    • inappropriate endpoint: Outcomes are immunostaining intensity and its correlation with histological grade, which are not clinical or safety outcomes.
    • no control group: Descriptive tissue-expression study with no comparison group and no intervention given.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 16949646, abstract (final two sentences) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 16949646, abstract (sentences 3-5) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 16949646, abstract (sentences 3-6) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 16949646, title (title) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).